Skip to main content
OGI
NASDAQ Life Sciences

Organigram Launches Edison & BOXHOT Medical Vapes and Pastilles in Australia

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.425
Mkt Cap
$192.569M
52W Low
$0.85
52W High
$2.24
52W Position info
68% above low
Off High info
36% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

OGI sits 68% above its 52-week low of $0.85 on light trading volume (0.3× avg).

Summary

Organigram Global Inc. is expanding its international product portfolio by launching Edison and BOXHOT medical cannabis vapes and pastilles in Australia, leveraging a distribution partnership to reach over 4,000 pharmacies.


Key Events · Product Development and Regulatory · OGI

  • Enters Australian Medical Cannabis Market

    Organigram has launched Edison and BOXHOT medical cannabis vape and pastille products in Australia, a dynamic and growing market.

  • Introduces 10 New Product SKUs

    The company is expanding its product portfolio in Australia with 10 new SKUs, focusing on non-flower formats like vapes and pastilles, which are gaining demand for consistent dosing and ease of administration.

  • Secures Broad Distribution

    Products will be available through a distribution partnership with Leafio (Montu Australia), providing access to over 4,000 pharmacies nationwide.

  • Aligns with Global Expansion Strategy

    This launch coincides with Organigram's proposed acquisition of Sanity Group in Germany, underscoring a broader strategy to reinforce its global medical cannabis presence.


Analysis · OGI · Life Sciences

This strategic expansion into Australia, a rapidly growing medical cannabis market, signifies Organigram's commitment to global growth and diversification. The introduction of 10 new product SKUs, particularly non-flower formats like vapes and pastilles, aligns with evolving patient preferences and strengthens the company's position as a key supplier. This move, explicitly linked to the recent Sanity Group acquisition, demonstrates execution on Organigram's international strategy and opens new revenue streams through a robust distribution network.

At the time of this filing, OGI was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.6M. The 52-week trading range was $0.85 to $2.24. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OGI - Latest Insights

OGI
Jul 20, 2026, 4:53 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.9293
Real-time Price: $0.9487 info
Change: +$0.0194 (+2%) info
Market Cap: $129.468M info
OGI
May 12, 2026, 7:43 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.9487 info
Change: -$0.1213 (-11%) info
Market Cap: $129.468M info
OGI
Apr 17, 2026, 8:33 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $1.56
Real-time Price: $0.9487 info
Change: -$0.6113 (-39%) info
Market Cap: $129.468M info
OGI
Apr 15, 2026, 7:50 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.54
Real-time Price: $0.9487 info
Change: -$0.5913 (-38%) info
Market Cap: $129.468M info
OGI
Mar 30, 2026, 9:55 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.31
Real-time Price: $0.9487 info
Change: -$0.3613 (-28%) info
Market Cap: $129.468M info